ActiTrexx has developed a cellular therapy with activated regulatory T cells (ATreg) to minimize the high risk of rejection after stem cell transplantation.
Location: Germany, Rhineland-Palatinate, Budenheim
Employees: 1-10
Total raised: $4.23M
Founded date: 2020
Investors 2
| Date | Name | Website |
| 02.03.2021 | LBBW Ventu... | lbbwvc.de |
| - | MediVentur... | medi.ventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.03.2021 | Series A | $4.23M | - |
Mentions in press and media 7
| Date | Title | Description |
| 20.06.2023 | Biotech Breakthroughs: Unraveling Germany’s 15 Emerging Biotechnology Startups | Emergence Therapeutics led by Jack Elands, is a promising biopharmaceutical company dedicated to advancing novel ADC immunotherapies to address cancers with high unmet needs. Table of Contents show 1 FaCellitate – Supporting Drug Discover... |
| 02.03.2021 | PRESS RELEASE: Newly founded biotech company ActiTrexx receives funding of EUR 3.5 million to develop cell therapy against transplant rejection | DGAP-News: ActiTrexx GmbH / Key word(s): Financing Newly founded biotech company ActiTrexx receives funding of EUR 3.5 million to develop cell therapy against transplant rejection 2021-03-02 / 09:00 The issuer is solely responsible for the ... |
| 02.03.2021 | PRESS RELEASE : Newly founded biotech company ActiTrexx receives funding of EUR 3.5 million to develop cell therapy against transplant rejection | DGAP-News: ActiTrexx GmbH / Key word(s): Financing Newly founded biotech company ActiTrexx receives funding of EUR 3.5 million to develop cell therapy against transplant rejection 2021-03-02 / 09:00 The issuer is solely responsible for the ... |
| 02.03.2021 | ActiTrexx GmbH : Newly founded biotech company ActiTrexx receives funding of ? 3.5 million to develop cell therapy against transplant rejection | DGAP-News: ActiTrexx GmbH / Key word(s): Financing Newly founded biotech company ActiTrexx receives funding of ? 3.5 million to develop cell therapy against transplant rejection 02.03.2021 / 09:00 The issuer is solely responsible for the co... |
| 02.03.2021 | ActiTrexx Raises €3.5M in Series A Funding | ActiTrexx GmbH, a new biotech spin-off from the University Medical Center Mainz, Germany, closed its €3.5m Series A financing. The round was led by LBBW Venture Capital GmbH with participation from MediVentures GmbH, High-Tech Gründerfonds ... |
| 03.02.2021 | ActiTrexx GmbH : Newly founded biotech company ActiTrexx receives funding of ? 3.5 million to develop cell therapy against transplant rejection | DGAP-News: ActiTrexx GmbH / Key word(s): Financing Newly founded biotech company ActiTrexx receives funding of ? 3.5 million to develop cell therapy against transplant rejection 02.03.2021 / 09:00 The issuer is solely responsible for the co... |
| - | Newly founded biotech company ActiTrexx receives funding of € 3.5 million to develop cell therapy against transplant rejection | ActiTrexx GmbH, a new biotech spin-off from the University Medical Center Mainz, Germany, has successfully closed its Series A financing. A consortium led by LBBW Venture Capital GmbH with participation from MediVentures GmbH, High-Tech Grü... |